Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial

By sjmartinez • May 28, 2023

John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 May 24:S1556-0864(23)00574-9. doi: 10.1016/j.jtho.2023.05.015. Epub ahead of print. PMID: 37236398.

Tags: Adjuvant, EGFR, Hematology/Oncology, Non-small cell lung cancer, Osimertinib, Publications, safety

Related Posts

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney[...]

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

Melisi D, Macarulla T, De La Fouchardière C, Pazo Cid RA, Chandana SR, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab[...]

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study

Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi[...]